Download PDF
Horm Metab Res 2002; 34(11/12): 698-702
DOI: 10.1055/s-2002-38257
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Glucocorticoid-Regulated Adipose Tissue Secretion of PAI-1, but not IL-6, TNFα or Leptin in Vivo

J.  Uddén 1 , P.  Eriksson 2 , J.  Hoffstedt 1
  • 1 Centre for metabolism and Endocrinology, Huddinge University Hospital, Stochholm, Sweden
  • 2 Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
Further Information

Publication History

Received 1 October 2002

Accepted after revision 26 November 2002

Publication Date:
27 March 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: Glucocorticoids are well-known regulators of adipose tissue metabolism and endocrine function. The aim of this study was to examine glucocorticoid effect on plasminogen activator inhibitor 1 (PAI-1), tumour necrosis factor alpha (TNFα), leptin and interleukin-6 (IL-6) adipose tissue secretion. Material and Methods: Twelve healthy postmenopausal women with mean BMI of 28.9 kg/m² (± 0.8 SEM) received 25 mg prednisolone daily for 7 days. Before and after glucocorticoid treatment adipose tissue secretion of PAI-1, leptin, IL-6 and TNFα were measured, and adipocyte PAI-1 mRNA as well as anthropometrical and bio-chemical data were obtained. Results: Anthropometric measurements remained unaffected. Analyses of venous blood-samples showed a borderline increase of insulin levels (p = 0.062). PAI-1 secretion from adipose tissue increased (1.9 ± 0.2 vs. 3.5 ± 0.5 ng/g triglycerides, p = 0.012), but PAI-1 mRNA levels did not (0.19 ± 0.02 vs. 0.21 ± 0.04 arbitrary units after normalised to β-actin, p = 0.51). There were no apparent differences in IL-6, TNFα or leptin secretion after glucocorticoid exposure. Conclusion: This study shows an increased secretion of PAI-1, but not IL-6, TNFα or leptin, from abdominal adipose tissue after in vivo glucocorticoid treatment, which may be a finding of pathophysiological importance given the well-known effect of glucocorticoid excess on metabolic aberrations and cardiovascular morbidity.

Key words

Adipose Tissue - Glucocorticoids - Obesity - PAI-1 and Protein Secretion

References

  • 1 Kirk L F, Hasch R B, Katner H P, Jones T. Cushing’s disease: clinical manifestations and diagnostic evaluation.  Amer Fam Physician. 2000;  62 1119-1127
    PubMedGoogle Scholar
  • 2 Rosmond R, Bjorntorp P. The interactions between hypothalamic-pituitary- adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men.  Int J Obes Relat Metab Disord. 1998;  22 1184-1196
    CrossrefPubMedGoogle Scholar
  • 3 Bjorntorp P, Rosmond R. Obesity and cortisol.  Nutrition. 2000;  16 924-926
    CrossrefPubMedGoogle Scholar
  • 4 Ottosson M, Lonnroth P, Bjorntorp P, Eden S. Effects of cortisol and growth hormone on lipolysis in human adipose tissue.  J Clin Endocrinol Metab. 2000;  85 799-825
    CrossrefPubMedGoogle Scholar
  • 5 Arner P. Regional differences in protein production by human adipose tissue.  Biochem Soc Trans. 2001;  29 72-75
    CrossrefPubMedGoogle Scholar
  • 6 Alessi M C, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis.  Horm Metab Res. 2000;  32 504-508
    PubMedGoogle Scholar
  • 7 Juhan-Vague I, Alessi M C, Morange P E. Hypofibrinolysis and increased PAI-1 are linked to atherosclerosis via insulin resistance and obesity.  Ann Med. 2000;  32 78-84
    PubMedGoogle Scholar
  • 8 Janand-Delenne B, Chagnaud C, Raccah D, Alessi M C, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women.  Int J Obes. 1998;  22 312-317
    CrossrefPubMedGoogle Scholar
  • 9 Patrassi G M, Sartori M T, Livi U, Casonato A, Danesin C, Vettore S, Girolami A. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation.  Transplantation. 1997;  64 1610-1614
    PubMedGoogle Scholar
  • 10 Mohamed-Ali V, Pinkney J H, Coppack S W. Adipose tissue as an endocrine and paracrine organ.  Int J Obes Relat Metab Disord. 1998;  22 1145-1158
    CrossrefPubMedGoogle Scholar
  • 11 Grimble R F. Inflammatory status and insulin resistance.  Curr Opin Clin Nutr Metab Care. 2002;  5 551-559
    CrossrefPubMedGoogle Scholar
  • 12 He G, Pedersen S B, Bruun J M, Richelsen B. Regulation of plasminogen activator inhibitor-1 in human adipose tissue; interaction between cytokines, cortisol and estrogen.  Horm Metab Res. 2000;  32 515-520
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Lasic S, Bobarevic N, Nikolin B. Simultaneous determination of prednisone, prednisolone, cortisol and dexamethasone in plasma by high-performance liquid chromatography.  J Pharm Biomed Anal. 1989;  7 777-782
    CrossrefPubMedGoogle Scholar
  • 14 Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations.  Am J Clin Nutr. 1988;  48 1351-1361
    PubMedGoogle Scholar
  • 15 Morange P E, Aubert J, Peiretti F, Lijnen H R, Vague P, Verdier M, Negrel R, Juhan-Vague I, Alessi M C. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.  Diabetes. 1999;  48 890-895
    CrossrefPubMedGoogle Scholar
  • 16 Seki T, Miyasu T, Noguchi T, Hamasaki A, Sasaki R, Ozawa Y, Okukita K, Declerck P J, Ariga T. Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.  Cell Physiol. 2001;  189 72-78
    PubMedGoogle Scholar
  • 17 Halleux C M, Declerck P J, Tran S L, Detry R, Brichard S M. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines.  J Clin Endocrinol Metab. 1999;  84 4097-4105
    CrossrefPubMedGoogle Scholar
  • 18 Sartori M T, Patrassi G M, Pontarollo S, Livi U, Angelini A, Theodoridis P, Fioretti M, Girolami A. relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.  J Heart Lung Transplant. 1999;  18 693-700
    PubMedGoogle Scholar
  • 19 Mohamed-Ali V, Pinkney J H, Panahloo A, Cwyfan-Hughes S, Holly J MP, Yudkin J S. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome.  Clin Endocrinol. 1999;  50 221-228
    CrossrefPubMedGoogle Scholar
  • 20 Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.  Diabetologia. 1998;  41 65-71
    CrossrefPubMedGoogle Scholar
  • 21 Alessi M C, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis.  Horm Metab Res. 2000;  32 504-508
    PubMedGoogle Scholar
  • 22 Patrassi G M, Sartori M T, Viero M L, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state.  Blood Coag Fibrinol. 1992;  3 789-793
    CrossrefPubMedGoogle Scholar
  • 23 Yamamoto K R. Steroid receptor regulated transcription of specific genes and gene networks.  A Rev Genet. 1985;  19 209-252
    CrossrefPubMedGoogle Scholar
  • 24 van Zonneveld A J, Curriden S A, Loskutoff D J. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter.  Proc Natl Acad Sci USA. 1988;  85 5525-5529
    CrossrefPubMedGoogle Scholar
  • 25 Brown N J, Kim K S, Chen Y Q, Blevins L S, Nadeau J H, Meranze S G, Vaughan D E. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1.  production. 2000;  85 336-344
    CrossrefPubMedGoogle Scholar
  • 26 Song C Z, Tian X, Gelehrter T D. Glucocorticoid receptor inhibits transforming growth factor-beta signalling by directly targeting the transcriptional activation function of Smad 3.  Proc Natl Acad Sci USA. 1999;  96 11 776-11 781
    PubMedGoogle Scholar
  • 27 Vincennati V, Vottero A, Friedman C, Papanicolaou D A. Hormonal regulation of interleukin-6 production in human adipocytes.  Int J Obes Relat Metab Disord. 2002;  26 905-911
    CrossrefPubMedGoogle Scholar
  • 28 Mazusaki H, Ogawa Y, Hosoda K, Miyawaki T, Hanaoka I, Hiraoka J, Yasuno A, Nishimura H, Yoshimasa Y, Nishi S, Nakao K. Glucocorticoid regulation of leptin synthesis and secretion in humans: Elevated plasma leptin levels in Cushing’s syndrome.  J Clin Endocrinol Metab. 1997;  82 2542-2547
    CrossrefPubMedGoogle Scholar
  • 29 Fried S K, Bunkin D A, Greenberg A S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.  J Clin Endocrinol. Metab1998;  83 847-850
    CrossrefPubMedGoogle Scholar
  • 30 Halleux C M, Servais I, Reul B A, Detry R, Brichard S M. Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity.  J Clin Endocrinol Metab. 1998;  83 902-909
    CrossrefPubMedGoogle Scholar
  • 31 Papaspyrou-Rao S, Schneider S H, Petersen R N, Fried S K. Dexamethasone increases leptin expression in humans in vivo.  J Clin Endocrinol Metab. 1997;  82 1635-1637
    CrossrefPubMedGoogle Scholar
  • 32 Berg A L, Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man - studies in vivo and in vitro.  Metabolism. 1994;  43 90-97
    CrossrefPubMedGoogle Scholar
  • 33 Berg A L, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.  Kidney Int. 1999;  56 1534-1543
    CrossrefPubMedGoogle Scholar
  • 34 McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism.  Diabetes Metab Rev. 1988;  4 17-30
    CrossrefPubMedGoogle Scholar

J. Hoffstedt, M.D., Ph.D.

Karolinska Institutet

M61, CME · Huddinge University Hospital · 141 86 Stockholm · Sweden ·

Phone: + 46 (8) 58 58 00 00

Email: johan.hoffstedt@medhs.ki.se